FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100516555> ?p ?o ?g. }

• W2100516555 endingPage "896" @default.
• W2100516555 startingPage "890" @default.
• W2100516555 abstract "Abstract Malignant peripheral nerve sheath tumors (MPNST) are soft-tissue tumors with a very poor prognosis and largely resistant to chemotherapy. MPNSTs are characterized by activation of the Ras pathway by loss of tumor suppressor neurofibromatosis type 1. In view of this, MPNST may be susceptible to inhibition of the activated Ras/Raf/mitogen-activated protein kinase pathway by the B-Raf inhibitor sorafenib. MPNST (MPNST and ST8814) and dedifferentiated liposarcoma (LS141 and DDLS) human tumor cell lines were characterized for Ras activation and B-Raf expression. Tumor cells were treated with sorafenib and examined for growth inhibition, inhibition of phospho-MEK, phospho-ERK, cell cycle arrest, and changes in cyclin D1 and pRb expression. MPNSTs were sensitive to sorafenib at nanomolar concentrations. This appeared to be due to inhibition of phospho-MEK, phospho-ERK, suppression of cyclin D1, and hypophosphorylation of pRb at the CDK4-specific sites, resulting in a G1 cell cycle arrest. These effects were not seen in the liposarcoma cells, which either did not express B-Raf or showed decreased Ras activation. Small interfering RNA–mediated depletion of B-Raf in MPNSTs also induced a G1 cell cycle arrest in these cells, with a marked inhibition of cyclin D1 expression and Rb phosphorylation, whereas depletion of C-Raf did not affect either. With growth inhibition at the low nanomolar range, sorafenib, by inhibiting the mitogen-activated protein kinase pathway, may prove to be a novel therapy for patients with MPNST. [Mol Cancer Ther 2008;7(4):890–6]" @default.
• W2100516555 created "2016-06-24" @default.
• W2100516555 creator A5006913373 @default.
• W2100516555 creator A5020566961 @default.
• W2100516555 creator A5026962347 @default.
• W2100516555 creator A5058570895 @default.
• W2100516555 creator A5061390917 @default.
• W2100516555 creator A5072876748 @default.
• W2100516555 creator A5082322231 @default.
• W2100516555 date "2008-04-01" @default.
• W2100516555 modified "2023-09-23" @default.
• W2100516555 title "Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells" @default.
• W2100516555 cites W1606749110 @default.
• W2100516555 cites W1965097080 @default.
• W2100516555 cites W1984375602 @default.
• W2100516555 cites W1987484997 @default.
• W2100516555 cites W2015015957 @default.
• W2100516555 cites W2020231002 @default.
• W2100516555 cites W2033250411 @default.
• W2100516555 cites W2041150663 @default.
• W2100516555 cites W2049171090 @default.
• W2100516555 cites W2052550764 @default.
• W2100516555 cites W2066441128 @default.
• W2100516555 cites W2072478579 @default.
• W2100516555 cites W2075091190 @default.
• W2100516555 cites W2080686146 @default.
• W2100516555 cites W2082777374 @default.
• W2100516555 cites W2086778602 @default.
• W2100516555 cites W2127150495 @default.
• W2100516555 cites W2131112007 @default.
• W2100516555 cites W2134410951 @default.
• W2100516555 cites W2140765540 @default.
• W2100516555 cites W2144501719 @default.
• W2100516555 cites W2188177426 @default.
• W2100516555 cites W2551773592 @default.
• W2100516555 doi "https://doi.org/10.1158/1535-7163.mct-07-0518" @default.
• W2100516555 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3267321" @default.
• W2100516555 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18413802" @default.
• W2100516555 hasPublicationYear "2008" @default.
• W2100516555 type Work @default.
• W2100516555 sameAs 2100516555 @default.
• W2100516555 citedByCount "65" @default.
• W2100516555 countsByYear W21005165552012 @default.
• W2100516555 countsByYear W21005165552013 @default.
• W2100516555 countsByYear W21005165552014 @default.
• W2100516555 countsByYear W21005165552015 @default.
• W2100516555 countsByYear W21005165552016 @default.
• W2100516555 countsByYear W21005165552017 @default.
• W2100516555 countsByYear W21005165552018 @default.
• W2100516555 countsByYear W21005165552019 @default.
• W2100516555 countsByYear W21005165552020 @default.
• W2100516555 countsByYear W21005165552021 @default.
• W2100516555 countsByYear W21005165552022 @default.
• W2100516555 countsByYear W21005165552023 @default.
• W2100516555 crossrefType "journal-article" @default.
• W2100516555 hasAuthorship W2100516555A5006913373 @default.
• W2100516555 hasAuthorship W2100516555A5020566961 @default.
• W2100516555 hasAuthorship W2100516555A5026962347 @default.
• W2100516555 hasAuthorship W2100516555A5058570895 @default.
• W2100516555 hasAuthorship W2100516555A5061390917 @default.
• W2100516555 hasAuthorship W2100516555A5072876748 @default.
• W2100516555 hasAuthorship W2100516555A5082322231 @default.
• W2100516555 hasBestOaLocation W21005165551 @default.
• W2100516555 hasConcept C11882975 @default.
• W2100516555 hasConcept C121608353 @default.
• W2100516555 hasConcept C126322002 @default.
• W2100516555 hasConcept C184235292 @default.
• W2100516555 hasConcept C185592680 @default.
• W2100516555 hasConcept C199835354 @default.
• W2100516555 hasConcept C204232928 @default.
• W2100516555 hasConcept C2778019345 @default.
• W2100516555 hasConcept C2778173781 @default.
• W2100516555 hasConcept C2778695046 @default.
• W2100516555 hasConcept C2781249067 @default.
• W2100516555 hasConcept C29537977 @default.
• W2100516555 hasConcept C502942594 @default.
• W2100516555 hasConcept C57074206 @default.
• W2100516555 hasConcept C71924100 @default.
• W2100516555 hasConcept C86803240 @default.
• W2100516555 hasConcept C95444343 @default.
• W2100516555 hasConcept C97029542 @default.
• W2100516555 hasConceptScore W2100516555C11882975 @default.
• W2100516555 hasConceptScore W2100516555C121608353 @default.
• W2100516555 hasConceptScore W2100516555C126322002 @default.
• W2100516555 hasConceptScore W2100516555C184235292 @default.
• W2100516555 hasConceptScore W2100516555C185592680 @default.
• W2100516555 hasConceptScore W2100516555C199835354 @default.
• W2100516555 hasConceptScore W2100516555C204232928 @default.
• W2100516555 hasConceptScore W2100516555C2778019345 @default.
• W2100516555 hasConceptScore W2100516555C2778173781 @default.
• W2100516555 hasConceptScore W2100516555C2778695046 @default.
• W2100516555 hasConceptScore W2100516555C2781249067 @default.
• W2100516555 hasConceptScore W2100516555C29537977 @default.
• W2100516555 hasConceptScore W2100516555C502942594 @default.
• W2100516555 hasConceptScore W2100516555C57074206 @default.
• W2100516555 hasConceptScore W2100516555C71924100 @default.
• W2100516555 hasConceptScore W2100516555C86803240 @default.
• W2100516555 hasConceptScore W2100516555C95444343 @default.

• next